InvestorsHub Logo
Followers 155
Posts 2642
Boards Moderated 0
Alias Born 01/29/2004

Re: Hoskuld post# 438770

Monday, 11/13/2023 5:28:05 PM

Monday, November 13, 2023 5:28:05 PM

Post# of 462189
Ok, then. Let’s see a big trial.

From the announcement:

The technology has been licensed from UC San Diego to a biotechnology startup Ampera Life.


Yes, this new biomarker analysis technology has been licensed to a young company, Ampera Life.

https://www.amperalife.com/

That’s good news. To be used the technology must be commercially available. Not possible with a mere prototype device used only to demonstrate the technology, resting on the bench of some university lab (in this case UC Sand Diego). With this contractual arrangement, Ampera can manufacture the devices that can be used in up-coming clinical trials.

Using the new biomarker analysis device wouldn’t it be interesting to see the data from a clinical Alzheimer’s trial comparing blarcamesine with Aricept, Aduhelm, Leqembi, or any of the others so wonderfully approved for clinical use.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News